This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tezacitabine

Novartis AG

Drug Names(s): Tezacitabine

Description: Tezacitabine is a novel nucleoside analog with a dual mechanism of action. It is both a potent inhibitor of ribonucleotide reductase and a DNA chain terminator. In pre-clinical studies, tezacitabine induces apoptosis and inhibits Vascular Endothelial Growth Factor (VEGF), which appears to be required for angiogenesis in many types of tumors. Tezacitabine has demonstrated synergism with radiation and with other marketed cytotoxic agents such as Ara-C and cisplatin.


Tezacitabine News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug